Avalo Therapeutics达成里程碑付款买断协议优化资本结构

投资观察

Apr 28

临床阶段生物技术公司Avalo Therapeutics Inc (纳斯达克: AVTX) 近日宣布，就2024年3月收购AlmataBio公司所涉条款达成里程碑付款买断协议。根据新签署的《里程碑买断选择权与修正协议》，该公司将支付225万美元获取一项选择权，可在协议生效后90日内行使。

通过该选择权，Avalo可选择以现金、普通股或组合形式支付512.5万美元，替代原定在III期临床试验首例患者给药时需支付的1500万美元或有里程碑款项。这一安排显著降低了公司的远期资金压力，为核心药物研发提供了更灵活的财务规划空间。

作为专注于开发IL-1β靶向疗法的生物技术企业，Avalo的主打候选药物abdalakibart（AVTX-009）目前正处于治疗化脓性汗腺炎的II期临床试验阶段。公司同时致力于拓展其他存在重大未满足临床需求的疾病领域。

本次协议涉及的财务安排体现了公司对资本配置的审慎考量。通过前置部分付款义务，Avalo在保留研发推进主动权的同时，有效规避了未来可能产生的高额里程碑付款风险。这种创新性的协议结构为生物科技行业的并购交易提供了新的范本。

（注：本文包含前瞻性陈述，实际结果可能因临床试验进展、监管环境变化等多项因素与陈述内容存在差异）

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1136316695"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1136316695\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1136316695?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-04-28 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136316695","market":"us","top_or_hot":-1,"title":"Avalo Therapeutics达成里程碑付款买断协议 优化资本结构","media":"投资观察","content":"<p>临床阶段生物技术公司Avalo Therapeutics Inc (纳斯达克: AVTX) 近日宣布，就2024年3月收购AlmataBio公司所涉条款达成里程碑付款买断协议。根据新签署的《里程碑买断选择权与修正协议》，该公司将支付225万美元获取一项选择权，可在协议生效后90日内行使。</p>\n<p>通过该选择权，Avalo可选择以现金、普通股或组合形式支付512.5万美元，替代原定在III期临床试验首例患者给药时需支付的1500万美元或有里程碑款项。这一安排显著降低了公司的远期资金压力，为核心药物研发提供了更灵活的财务规划空间。</p>\n<p>作为专注于开发IL-1β靶向疗法的生物技术企业，Avalo的主打候选药物abdalakibart（AVTX-009）目前正处于治疗化脓性汗腺炎的II期临床试验阶段。公司同时致力于拓展其他存在重大未满足临床需求的疾病领域。</p>\n<p>本次协议涉及的财务安排体现了公司对资本配置的审慎考量。通过前置部分付款义务，Avalo在保留研发推进主动权的同时，有效规避了未来可能产生的高额里程碑付款风险。这种创新性的协议结构为生物科技行业的并购交易提供了新的范本。</p>\n<p>（注：本文包含前瞻性陈述，实际结果可能因临床试验进展、监管环境变化等多项因素与陈述内容存在差异）</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avalo Therapeutics达成里程碑付款买断协议 优化资本结构</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvalo Therapeutics达成里程碑付款买断协议 优化资本结构\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1076224072\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">投资观察 </p>\n<p class=\"h-time\">2026-04-28 19:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>临床阶段生物技术公司Avalo Therapeutics Inc (纳斯达克: AVTX) 近日宣布，就2024年3月收购AlmataBio公司所涉条款达成里程碑付款买断协议。根据新签署的《里程碑买断选择权与修正协议》，该公司将支付225万美元获取一项选择权，可在协议生效后90日内行使。</p>\n<p>通过该选择权，Avalo可选择以现金、普通股或组合形式支付512.5万美元，替代原定在III期临床试验首例患者给药时需支付的1500万美元或有里程碑款项。这一安排显著降低了公司的远期资金压力，为核心药物研发提供了更灵活的财务规划空间。</p>\n<p>作为专注于开发IL-1β靶向疗法的生物技术企业，Avalo的主打候选药物abdalakibart（AVTX-009）目前正处于治疗化脓性汗腺炎的II期临床试验阶段。公司同时致力于拓展其他存在重大未满足临床需求的疾病领域。</p>\n<p>本次协议涉及的财务安排体现了公司对资本配置的审慎考量。通过前置部分付款义务，Avalo在保留研发推进主动权的同时，有效规避了未来可能产生的高额里程碑付款风险。这种创新性的协议结构为生物科技行业的并购交易提供了新的范本。</p>\n<p>（注：本文包含前瞻性陈述，实际结果可能因临床试验进展、监管环境变化等多项因素与陈述内容存在差异）</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVTX","symbol_name":"Avalo Therapeutics Inc","start_time":0,"source_url":"","article_id":"1136316695","we_media_id":"1076224072","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136316695","pubTimestamp":1777374917,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"投资观察","introduction":"关注海外资本市场一手动态","home_visible":1,"id":"1076224072","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"临床阶段生物技术公司Avalo Therapeutics Inc  近日宣布，就2024年3月收购AlmataBio公司所涉条款达成里程碑付款买断协议。通过该选择权，Avalo可选择以现金、普通股或组合形式支付512.5万美元，替代原定在III期临床试验首例患者给药时需支付的1500万美元或有里程碑款项。通过前置部分付款义务，Avalo在保留研发推进主动权的同时，有效规避了未来可能产生的高额里程碑付款风险。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"AVTX":"Avalo Therapeutics Inc","BK4007":"制药","BK4539":"次新股","LENZ":"Therapeutics","BK4139":"生物科技"},"translate_title":"Avalo Therapeutics reaches milestone payment buyout agreement to optimize capital structure","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"AVTX":1},"content_text":"临床阶段生物技术公司Avalo Therapeutics Inc (纳斯达克: AVTX) 近日宣布，就2024年3月收购AlmataBio公司所涉条款达成里程碑付款买断协议。根据新签署的《里程碑买断选择权与修正协议》，该公司将支付225万美元获取一项选择权，可在协议生效后90日内行使。\n通过该选择权，Avalo可选择以现金、普通股或组合形式支付512.5万美元，替代原定在III期临床试验首例患者给药时需支付的1500万美元或有里程碑款项。这一安排显著降低了公司的远期资金压力，为核心药物研发提供了更灵活的财务规划空间。\n作为专注于开发IL-1β靶向疗法的生物技术企业，Avalo的主打候选药物abdalakibart（AVTX-009）目前正处于治疗化脓性汗腺炎的II期临床试验阶段。公司同时致力于拓展其他存在重大未满足临床需求的疾病领域。\n本次协议涉及的财务安排体现了公司对资本配置的审慎考量。通过前置部分付款义务，Avalo在保留研发推进主动权的同时，有效规避了未来可能产生的高额里程碑付款风险。这种创新性的协议结构为生物科技行业的并购交易提供了新的范本。\n（注：本文包含前瞻性陈述，实际结果可能因临床试验进展、监管环境变化等多项因素与陈述内容存在差异）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}